Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Respironics -- Ignore unavailable to you. Want to Upgrade?

To: Andy H who wrote (54)	12/19/1997 9:28:00 AM
From: Thean	Read Replies (1) \| Respond to of 103

Great News!!! Merger is through the FTC! HDTC is already bidding up. $24 and $20 is a 20% spread folks. In this crazy market this is low risk indeed. Load up HDTC. MARIETTA, Ga., Dec. 19 /PRNewswire/ -- Healthdyne Technologies, Inc. (NASDAQ:HDTC) announced today that the Hart-Scott-Rodino waiting period has expired. Accordingly, this condition to the Company's merger agreement with Respironics, Inc. has been satisfied. The Company announced on November 11, 1997 that it entered into a definitive agreement to merge with Respironics whereby each share of Healthdyne Technologies stock then outstanding will be converted into the right to receive between approximately .7734 and approximately .9220 shares of Respironics common stock depending on Respironics' Transaction Share Price determined as specified in the Merger Agreement. Healthdyne Technologies designs, manufactures and markets technologically advanced medical devices for use in the home, as well as other specialized clinical settings. The Company's products include diagnostic and therapeutic devices for the evaluation and treatment of sleep disorders, non-invasive ventilators, oxygen concentrators and medication nebulizers for the treatment of respiratory disorders, monitors for infants at risk for SIDS, and products for asthma management. This press release contains forward-looking statements that involve risks and uncertainties, including developments in the healthcare industry, development and introduction of new products on a timely basis, favorable resolution of intellectual property matters, third-party reimbursement policies and practices and regulatory requirements affecting the approval and sale of medical devices, as well as other risks detailed from time to time in the Company's reports filed with the Securities and Exchange Commission, including its Reports on Form 10-K, 8-K and 10Q.

To: Andy H who wrote (54)	1/12/1998 8:40:00 PM
From: Thean	Read Replies (2) \| Respond to of 103

Andy or anyone, has anybody received the shareholder voting proxy for the merger with HDTC? I have yet to receive it and am a HDTC shareholder who is trying hard to understand why HDTC tanks together with RESP today. I'd like to know if there is certain clause in the deal that says the merger is off if certain things happens. If HDTC is getting approximately $24, why has HDTC not trading closer to $24 since the merger announcement?